BioMarin Pharma (BMRN) has announced a preclinical collaboration and license agreement with DiNAQOR AGto develop novel gene therapies to treat rare genetic heart diseases.“We like BMRN as an established leader in rare diseases with a well-appreciated sustainable base business and promising long-term growth prospects in hemophilia A (BMN-270)” commented RBC Capital analyst Kennen MacKay on April 30.